Objective To evaluate curative effects and safety of mirtazapine and sertraline in the treatment of depression. Methods A total of 90 depression patients were randomly divided into research group and control group, with 45 cases in each group. The research group received mirtazapine for treatment, and the control group received sertraline for treatment. Their clinical effects were evaluated by Hamilton depression scale (HAMD) and clinical global impression and severity of illness scale (CGI-SI) before treatment and at the end of 1, 2, 4, 6 weeks of treatment. Adverse reactions were evaluated by treatment emergent symptom scale (TESS). Results Total effective rate was 86.7%in the research group and 84.4%in the control group, and the difference between the two groups had no statistical significance (P>0.05). Both groups had obviously decreased scores in CGI-SI after treatment than those before treatment (P<0.05), while the difference between the two groups had no statistical significance (P>0.05). After treatment, both groups had lower HAMD scores than those before treatment (P<0.05). The research group also had statistically significant differences of HAMD scores at the end of 1 and 2 weeks of treatment, comparing with the control group (P<0.05), while their differences at the other time points had no statistical significance (P>0.05). The research group had fewer adverse reactions than the control group (P<0.05). Conclusion Mirtazapine and sertraline provides generally equivalent effects, while mirtazapine has quicker effects and few adverse reaction.%目的：评价米氮平与舍曲林治疗抑郁症的疗效及安全性。方法90例抑郁症患者随机分为研究组和对照组，每组45例，研究组给予米氮平治疗，对照组给予舍曲林治疗。于治疗前及治疗1、2、4、6周末采用汉密尔顿抑郁量表(HAMD)及临床总体印象量表(CGI-SI)评定临床疗效，副反应量表(TESS)评定不良反应。结果研究组总有效率为86.7%，对照组总有效率为84.4%，两组比较差异无统计学意义(P>0.05)；两组CGI-SI评分较治疗前均有显著下降(P<0.05)，但组间比较差异无统计学意义(P>0.05)；治疗后两组HAMD评分均较治疗前下降(P<0.05)，且研究组治疗第1、2周末HAMD总分和对照组比较差异有统计学意义(P<0.05)，其他时点评分差异均无统计学意义(P>0.05)；研究组不良反应较对照组更少，差异有统计学意义(P<0.05)。结论米氮平与舍曲林，总体疗效相当，米氮平起效更快，不良反应更少。
展开▼
